Literature DB >> 32056068

Comparison of cytokine profiles between anti-ARS antibody-positive interstitial lung diseases and those with anti-MDA-5 antibodies.

Katsuaki Asakawa1, Kazutaka Yoshizawa1, Ami Aoki1, Yosuke Kimura1, Takahiro Tanaka2, Kazumasa Ohashi1,3, Masachika Hayashi1, Toshiaki Kikuchi1, Shinji Sato4, Toshinori Takada5,6.   

Abstract

INTRODUCTION/
OBJECTIVES: Interstitial lung disease (ILD) is a significant cause of mortality among patients with dermatomyositis (DM) or polymyositis (PM). There are two subtypes of PM and DM often complicated with ILD: those with anti-aminoacyl-tRNA synthetase (anti-ARS) antibodies and those with anti-MDA-5-associated amyopathic DM (ADM). Our aim is to clarify the inflammatory and immunological differences between the disorders.
METHODS: We retrospectively collected consecutive patients with anti-ARS-ILD and those with anti-MDA-5 antibody-positive ADM-ILD. The serum concentration of 38 cytokines was measured using a cytokine panel. The relative risks for anti-MDA-5 antibody-positive ADM-ILD were examined with univariate and multivariate logistic regression models. Spearman's rank correlation coefficient was calculated between cytokine levels and clinical parameters in the disease. Levels of cytokines were compared between anti-ARS-ILD and anti-MDA-5-positive ADM-ILD patients (alive or dead) using Dunnett's test.
RESULTS: Twenty-three patients with anti-ARS-ILD and the same number of patients with anti-MDA-5-positive ADM-ILD were enrolled. The anti-MDA-5 group had poor survival (p = 0.025). Univariate logistic regression models showed that eotaxin, IL-10, IP-10, and MCP-1 were associated with the diagnosis of anti-MDA-5-positive ADM-ILD. Multivariate logistic regression models revealed that IP-10 was the most significantly associated (p = 0.001). Relationship analyses showed that IL-10 had significant positive correlations with CK (r = 0.5267, p = 0.009) and ferritin (r = 0.4528, p = 0.045). A comparison of the cytokine levels found that IP-10 was elevated in both patients who were alive and patients who had died with ADM-ILD compared with the levels in those with ARS-ILD (p = 0.003 and p = 0.001, respectively).
CONCLUSIONS: Anti-MDA-5-positive ADM-ILD had poorer survival than anti-ARS-ILD. IP-10 seems to be most deeply involved in the pathophysiology of anti-MDA-5-associated ADM-ILD.Key Points• To clarify differences in the inflammatory and immunological features of anti-MDA-5-positive ADM-ILD and anti-ARS-ILD, we performed an observational study to measure serum cytokine concentrations before treatment using a multiplex immunoassay system.• Multivariate logistic regression models revealed that IP-10 was associated with the most significant relative risk for ADM-ILD with anti-MDA-5 antibodies.• Levels of IP-10 were elevated considerably in anti-MDA-5-positive survivors and nonsurvivors compared with the levels in anti-ARS patients.• These results suggest that IP-10 is the most deeply involved in the pathophysiology of anti-MDA-5-positive ADM-ILD.

Entities:  

Keywords:  Anti-MDA-5 antibody; Anti-aminoacyl-tRNA synthetase; Cytokines; Dermatomyositis; Interstitial lung disease

Mesh:

Substances:

Year:  2020        PMID: 32056068     DOI: 10.1007/s10067-020-04984-x

Source DB:  PubMed          Journal:  Clin Rheumatol        ISSN: 0770-3198            Impact factor:   2.980


  28 in total

1.  RNA helicase encoded by melanoma differentiation-associated gene 5 is a major autoantigen in patients with clinically amyopathic dermatomyositis: Association with rapidly progressive interstitial lung disease.

Authors:  Shinji Sato; Kana Hoshino; Takashi Satoh; Tomonobu Fujita; Yutaka Kawakami; Takashi Fujita; Masataka Kuwana
Journal:  Arthritis Rheum       Date:  2009-07

2.  Association of anti-aminoacyl-transfer RNA synthetase antibody and anti-melanoma differentiation-associated gene 5 antibody with the therapeutic response of polymyositis/dermatomyositis-associated interstitial lung disease.

Authors:  Naomi Yoshida; Masaki Okamoto; Shinjiro Kaieda; Kiminori Fujimoto; Tomohiro Ebata; Morihiro Tajiri; Masayuki Nakamura; Masaki Tominaga; Daisuke Wakasugi; Tomotaka Kawayama; Masataka Kuwana; Tsuneyo Mimori; Hiroaki Ida; Tomoaki Hoshino
Journal:  Respir Investig       Date:  2016-09-30

3.  Comprehensive assessment of myositis-specific autoantibodies in polymyositis/dermatomyositis-associated interstitial lung disease.

Authors:  Hironao Hozumi; Tomoyuki Fujisawa; Ran Nakashima; Takeshi Johkoh; Hiromitsu Sumikawa; Akihiro Murakami; Noriyuki Enomoto; Naoki Inui; Yutaro Nakamura; Yuji Hosono; Yoshitaka Imura; Tsuneyo Mimori; Takafumi Suda
Journal:  Respir Med       Date:  2016-11-02       Impact factor: 3.415

4.  Clinical characteristics of patients with anti-aminoacyl-tRNA synthetase antibody positive idiopathic interstitial pneumonia.

Authors:  Hirokazu Yura; Noriho Sakamoto; Minoru Satoh; Hiroshi Ishimoto; Tetsuya Hanaka; Chiyo Ito; Tomoko Hasegawa; Shin Tanaka; Takuto Miyamura; Shota Nakashima; Atsuko Hara; Tomoyuki Kakugawa; Keishi Oda; Takashi Kido; Yasushi Obase; Yuji Ishimatsu; Kazuhiro Yatera; Atsushi Kawakami; Hiroshi Mukae
Journal:  Respir Med       Date:  2017-10-28       Impact factor: 3.415

5.  Role of IL-15 in interstitial lung diseases in amyopathic dermatomyositis with anti-MDA-5 antibody.

Authors:  Toshinori Takada; Kazumasa Ohashi; Masachika Hayashi; Katsuaki Asakawa; Takuro Sakagami; Toshiaki Kikuchi; Shinji Sato
Journal:  Respir Med       Date:  2018-06-15       Impact factor: 3.415

6.  The long-term outcome of interstitial lung disease with anti-aminoacyl-tRNA synthetase antibodies.

Authors:  Kiminobu Tanizawa; Tomohiro Handa; Ran Nakashima; Takeshi Kubo; Yuji Hosono; Kizuku Watanabe; Kensaku Aihara; Kohei Ikezoe; Akihiko Sokai; Yoshinari Nakatsuka; Yoshio Taguchi; Kazuhiro Hatta; Satoshi Noma; Yoichiro Kobashi; Akihiko Yoshizawa; Toru Oga; Toyohiro Hirai; Kazuo Chin; Sonoko Nagai; Takateru Izumi; Tsuneyo Mimori; Michiaki Mishima
Journal:  Respir Med       Date:  2017-04-15       Impact factor: 3.415

7.  Dermatomyositis with hemorrhagic myositis.

Authors:  Masashi Yamagishi; Shunji Tajima; Aki Suetake; Hidenori Kawakami; Takeo Watanabe; Hideyuki Kuriyama; Toshinori Takada; Eiichi Suzuki; Fumitake Gejyo
Journal:  Rheumatol Int       Date:  2008-12-17       Impact factor: 2.631

Review 8.  Autoantibodies in idiopathic inflammatory myopathy: an update on clinical and pathophysiological significance.

Authors:  Tsuneyo Mimori; Yoshitaka Imura; Ran Nakashima; Hajime Yoshifuji
Journal:  Curr Opin Rheumatol       Date:  2007-11       Impact factor: 5.006

9.  Anti-MDA5 antibody as a potential diagnostic and prognostic biomarker in patients with dermatomyositis.

Authors:  Liubing Li; Qian Wang; Funing Yang; Chanyuan Wu; Si Chen; Xiaoting Wen; Chenxi Liu; Yongzhe Li
Journal:  Oncotarget       Date:  2017-04-18

10.  EULAR/ACR classification criteria for adult and juvenile idiopathic inflammatory myopathies and their major subgroups: a methodology report.

Authors:  Matteo Bottai; Anna Tjärnlund; Giola Santoni; Victoria P Werth; Clarissa Pilkington; Marianne de Visser; Lars Alfredsson; Anthony A Amato; Richard J Barohn; Matthew H Liang; Jasvinder A Singh; Rohit Aggarwal; Snjolaug Arnardottir; Hector Chinoy; Robert G Cooper; Katalin Danko; Mazen M Dimachkie; Brian M Feldman; Ignacio García-De La Torre; Patrick Gordon; Taichi Hayashi; James D Katz; Hitoshi Kohsaka; Peter A Lachenbruch; Bianca A Lang; Yuhui Li; Chester V Oddis; Marzena Olesinka; Ann M Reed; Lidia Rutkowska-Sak; Helga Sanner; Albert Selva-O'Callaghan; Yeong Wook Song; Jiri Vencovsky; Steven R Ytterberg; Frederick W Miller; Lisa G Rider; Ingrid E Lundberg
Journal:  RMD Open       Date:  2017-11-14
View more
  2 in total

1.  Hierarchical cluster analysis of cytokine profiles reveals a cutaneous vasculitis-associated subgroup in dermatomyositis.

Authors:  Jingjing Bai; Chanyuan Wu; Danli Zhong; Dong Xu; Qian Wang; Xiaofeng Zeng
Journal:  Clin Rheumatol       Date:  2020-08-14       Impact factor: 2.980

2.  The Expression of Cytokine Profiles and Related Receptors in Idiopathic Inflammatory Myopathies.

Authors:  Junyu Zhou; Lijuan Zhao; Yizhi Xiao; Shasha Xie; Ying Long; Yu Wei; Qiming Meng; Xiaojing Li; Hui Luo; Honglin Zhu
Journal:  Front Pharmacol       Date:  2022-04-20       Impact factor: 5.988

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.